Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2002

View Archived Issues

Efficacy of rosiglitazone in ameliorating acute and chronic colitis

BIRB-796BS investigated in humans for safety, pharmacokinetics and pharmacodynamics

Alefacept is nonimmunogenic according to prospective analysis of phase III data

Inhibition of IL-8 appears to be involved in the cardioprotective mechanism of FR-183998

Comparison of safety and efficacy of three drugs for the treatment of obesity

FDA approves Remicade for improvement of physical function in RA

Shire summarizes quarter's R&D highlights

Effects of rhuIL-4R on antigen-specific T-cells may contribute to its clinical efficacy

Dosing will not resume in study of AN-1792 in Alzheimer's disease

FDA accepts Zetia NDA filing for hypercholesterolemia

Connetics' sNDA for Olux accepted by FDA

FDA finds Imavist approvable in echocardiography

AAAAI news: potential beneficial effects of Flt3 ligand in asthma

Third dendritic cell-based immunotherapy from Northwest Biotherapeutics cleared for clinical trials

Novartis prepares and tests PARP inhibitors

Compounds inhibiting the production of IL-2 in T-lymphocytes patented by Boehringer Ingelheim

Agonists of group I metabotropic glutamate receptors prepared by Roche

Roche reports antagonists of group I mglu receptors with potential in epilepsy, etc.

New patent covers compounds for conditions associated with undesirable bone resorption

Servier identifies compounds with potential in cognitive disorders

Beta3-adrenoceptor agonists claimed for the treatment of obesity and type 2 diabetes

Macrocyclic compounds useful as contrast agents for magnetic resonance imaging

Ridogrel has no significant efficacy in the treatment of ulcerative colitis

Limited activity of BMS-182751 as a treatment for recurrent cervical cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...